All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Koselugo 25mg Capsule
Prescription Required
Salt Composition : Selumetinib
Manufacturer : ASTRAZENECA PHARMA INDIA LTD
Origin of Medicine : United Kingdom
60 Capsule(s) In A Bottle
PAP Information : Contact us for latest updates
Koselugo 25mg Capsule
Program Overview: ASTRAZENECA PHARMA INDIA LTD, Patient Assistance Program (PAP) is dedicated to helping patients in need of the Koselugo 25mg Capsule. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Patient assistance programs (PAPs) are sponsored by pharmaceutical companies, and are an important step towards lowering overall therapy costs for patients. The purpose of these initiatives is to provide financial assistance to patients so they can obtain drugs at low or no cost. MrMed will guide you through the procedure and ensure you receive your PAP medication correctly.
Contact us for the latest updates on this exclusive offer.
Eligibility Criteria: To qualify for the Koselugo Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Selumetinib from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Astrazenca Pharma India Ltd can avail of it without having to purchase the medication from MrMed.
Patient Assistance Programs
Koselugo 25mg Capsule
Program Overview: ASTRAZENECA PHARMA INDIA LTD, Patient Assistance Program (PAP) is dedicated to helping patients in need of the Koselugo 25mg Capsule. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Patient assistance programs (PAPs) are sponsored by pharmaceutical companies, and are an important step towards lowering overall therapy costs for patients. The purpose of these initiatives is to provide financial assistance to patients so they can obtain drugs at low or no cost. MrMed will guide you through the procedure and ensure you receive your PAP medication correctly.
Contact us for the latest updates on this exclusive offer.
Eligibility Criteria: To qualify for the Koselugo Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Selumetinib from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Astrazenca Pharma India Ltd can avail of it without having to purchase the medication from MrMed.
Introduction to Koselugo 25mg Capsule
Koselugo 25mg Capsule contains an active component called Selumetinib. It is a medication used in the treatment of certain types of cancers, particularly melanoma (a type of skin cancer) and other solid tumors, including non-small cell lung cancer and ovarian cancer, especially in cases where there's a specific genetic mutation that makes the cancer cells sensitive to MEK inhibitors. It may be prescribed for patients with advanced melanoma that has a specific genetic mutation, often BRAF-mutant melanoma. It has shown promise in treating plexiform neurofibromas, tumors associated with NF1, a genetic disorder that causes tumors to grow on nerves.
Individuals who have had a severe allergic reaction to Koselugo 25mg Capsule or any of its components should not take this medication. It may cause harm to an unborn baby, so it is not recommended for use during pregnancy. Patients with pre-existing heart conditions or a history of heart problems may need close monitoring or might not be suitable candidates for this medication. Older individuals, especially those over 65, may have an increased risk of certain side effects. Close monitoring for adverse reactions is typically recommended after taking this medication. The safety and efficacy of Koselugo 25mg Capsule in children under specific ages may not be well-established.
Uses of Koselugo 25mg Capsule
Uses of Koselugo 25mg Capsule
- Melanoma treatment
- Neurofibromatosis type 1 (NF1)
- Solid tumor treatment
Therapeutic Effects of Koselugo 25mg Capsule
Koselugo 25mg Capsule is a medication that targets a specific cellular pathway called the MEK pathway, which is crucial for regulating cell growth. In cancers like melanoma and certain tumors, it blocks this pathway, disrupting signals that promote uncontrolled cell growth. By inhibiting this pathway, it slows down or halts the progression of cancer cells, reducing tumor growth and spread.
Interaction of Koselugo 25mg Capsule with other drugs
Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with the Koselugo 25mg Capsule, reducing effectiveness by causing undesirable side effects.
More Information about Koselugo 25mg Capsule
More information:
- Stored at controlled room temperature, between 20°C to 25°C
- Keep away from moisture, heat, and light.
- It should not be frozen.
- Keep away from children and pets.
How to consume Koselugo 25mg Capsule
Koselugo 25mg Capsule is primarily administered orally, typically as capsules. The healthcare provider will determine the dosage and duration of treatment based on the specific infection and individual factors.
Safety Advices for Koselugo 25mg Capsule
Pregnancy
It is not safe to take Koselugo 25mg Capsule during pregnancy as it may cause harm to the unborn baby.
Breast Feeding
It is not safe to breastfeed while taking Koselugo 25mg Capsule, as it may pass into breast milk and harm the infant.
Lungs
Consult your health care provider before taking Koselugo 25mg Capsule if you have lung disease.
Liver
If you have a liver condition or are concerned about the safety of Koselugo 25mg Capsule, it is recommended to consult your healthcare provider for personalized advice.
Alcohol
There are no specific interactions between alcohol and Koselugo 25mg Capsule, but alcohol consumption might exacerbate certain side effects, such as dizziness or liver-related problems. It is advisable to consult a healthcare professional regarding alcohol consumption while on this medication.
Driving
Taking Koselugo 25mg Capsule while driving is unsafe as it might cause dizziness or visual disturbances as side effects, which could affect the ability to drive or operate machinery.
Side Effects of Koselugo 25mg Capsule
Koselugo 25mg Capsule causes some side effects like all medications, although not everyone will experience them.
Serious:
- Heart problems
- Eye problems
- Interstitial lung disease (ILD)
- Liver problems
- Skin toxicities
Common:
- Nausea and vomiting
- Diarrhea
- Fatigue
- Skin rash
- Swelling or fluid retention
Word of Advice
Regular monitoring of heart function, including ECGs and cardiac assessments, may be necessary due to potential heart-related side effects while using Koselugo 25mg Capsule. Periodic eye exams are recommended as this medication might cause vision changes or retinal vein occlusion. Patients require monitoring for signs of interstitial lung disease (ILD) or breathing difficulties. Monitoring liver function through blood tests is essential due to the potential for elevated liver enzymes or liver damage. Live vaccines should generally be avoided during treatment due to potential complications. Regular monitoring might be necessary for individuals with existing endocrine conditions. Discuss with a healthcare professional regarding other medications, including over-the-counter drugs, herbal supplements, or vitamins, to avoid potential interactions with this medication.
FAQs
Q 1. What are the common side effects of Koselugo 25mg Capsule?
Common side effects of Koselugo 25mg Capsule may include nausea, vomiting, diarrhea, fatigue, skin rash, and swelling.
Q 2. Are there any dietary restrictions while taking Koselugo 25mg Capsule?
No specific dietary restrictions are known while taking Koselugo 25mg Capsule, but following a balanced diet is advisable unless otherwise instructed by a healthcare professional.
Q 3. What should I do if I miss a dose of Koselugo 25mg Capsule?
If you miss a dose of Koselugo 25mg Capsule, take it as soon as you remember unless it's close to the next scheduled dose. Do not double the dose to catch up. Contact your healthcare provider for guidance.
Q 4. How long does it take for Koselugo 25mg Capsule to work?
The response to Koselugo 25mg Capsule can vary among individuals. Some may experience a reduction in tumor size or symptoms within weeks to months, while others may take longer to see noticeable effects.
Q 5. Can Koselugo 25mg Capsule cure cancer?
Koselugo 25mg Capsule is a treatment that aims to control the growth and spread of cancer cells. It may shrink tumors and improve symptoms, but its ability to completely cure cancer varies based on individual circumstances and the type and stage of cancer.
Q 6. How often must I undergo medical tests while taking Koselugo 25mg Capsule?
The frequency of medical tests for Koselugo 25mg Capsule, such as blood tests or imaging studies, will depend on individual factors and your healthcare provider's recommendations. Monitoring is often necessary to manage potential side effects and track treatment progress.
Fact Box of Koselugo 25mg Capsule
Molecule name: Selumetinib | Therapeutic class: Antineoplastic agents |
Pharmacological class: Mitogen-activated protein Kinase (MAPK) inhibitor | Indications: 1. Melanoma treatment 2. Neurofibromatosis type 1 (NF1) 3. Solid tumor treatment |
References
- MARC R THEORET, Food and Drug Administration (FDA),[Revised on April 2020] [ Accessed on 15th Nov 2023]
- AstraZeneca UK Limited, Electronic medicines compendium (EMC), [ Revised on 15 Mar 2023] [ Accessed on 15th Nov 2023], https://www.medicines.org.uk/emc/product/12948/pil#gref
Disclaimer
MrMed’s primary intention is to ensure that its consumers get expert, accurate, and trustworthy information. The information and contents of this website are for informational purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Please seek your doctor's advice and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
4000+ products
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
Secure Payment
100% secure and trusted payment protection
Easy Return
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.
